Shandong Quanzhong Biomedical Technology

Shandong Quanzhong Biomedical Technology is a Chinese biotechnology company and an associate of Luye Pharma Group. The company specializes in the discovery and development of innovative small molecule therapies for central nervous system (CNS) disorders, metabolic diseases, and inflammatory conditions. Its lead clinical candidate, LPM5260558 (also known as LY02003), is currently in Phase 1 clinical trials for the treatment of acute ischemic stroke. Additionally, the company maintains a robust preclinical pipeline featuring RIPK1 inhibitors and monoamine transmitter reuptake inhibitors targeting a wide range of indications, including Alzheimer's disease, depression, and various autoimmune and inflammatory diseases. Shandong Quanzhong leverages its strategic relationship with Luye Pharma to advance its drug discovery efforts and clinical development programs.